Sign inJoin waitlistJoin the waitlist

Svetomir N. Markovic

Consultant, Division of Medical Oncology, Department of Oncology · Mayo Clinic

Credentials: · · ·

History

Mayo Clinic
Present

Research

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2019 · 739 citations
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Journal of Clinical Oncology · 2008 · 571 citations
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis
Review · Mayo Clinic Proceedings · 2007 · First of 18 authors · 313 citations

Luis Porrata
73 papers · 6 as a fellow
Lisa Kottschade
56 papers
Stephen Ansell
51 papers
DI
David Inwards
50 papers
Ivana Micallef
48 papers
Patrick Johnston
42 papers
Roxana Dronca
36 papers
Robert McWilliams
33 papers · 1 as a fellow
Matthew Block
32 papers · 3 as a fellow
Thomas Habermann
28 papers
Thomas Witzig
28 papers
James Jakub
24 papers

Grants

Quantitative Assessment of Pre-Metastatic Immune Subversion as a Risk Factor for Melanoma Relapse
National Cancer Institute · R01
Contact PI · $3M · Mayo Clinic Rochester
2022–2027
IL-2 Scintigraphy as a Guide to Cancer Immunotherapy
National Cancer Institute · R21
Contact PI · $631.3K · Mayo Clinic Rochester
2012–2015
Systemic Auto-Immunization Against Cancer Using Modified Radiofrequency Ablation
National Cancer Institute · R21
Contact PI · $680K · Mayo Clinic Rochester
2008–2011
B7-DC Cross-Linking Antibody Immunotherapy
National Cancer Institute · R21
Contact PI · $570.9K · Mayo Clinic Rochester
2007–2010

Clinical trials

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Principal investigator · Withdrawn · Phase 1
Mayo Clinic
2025–2026
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
Principal investigator · Recruiting
Mayo Clinic
2024–2027
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Principal investigator · Recruiting
Mayo Clinic
2015–2028
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
Principal investigator · Completed · Early phase 1
Mayo Clinic
2014–2018